Iaso Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 24-10-2024
- Paid Up Capital ₹ 0.50 M
as on 24-10-2024
- Company Age 13 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -14.50%
(FY 2023)
- Profit -21.02%
(FY 2023)
- Ebitda -38.39%
(FY 2023)
- Net Worth 11.21%
(FY 2023)
- Total Assets 8.96%
(FY 2023)
About Iaso Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Narender Chopra and Keshav Chopra serve as directors at the Company.
- CIN/LLPIN
U24232DL2011PTC214139
- Company No.
214139
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Feb 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Iaso Pharmaceuticals Private Limited offer?
Iaso Pharmaceuticals Private Limited offers a wide range of products and services, including Pharmacy Dropshipper, Drop Shipping Services.
Who are the key members and board of directors at Iaso Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Narender Chopra  | Managing Director | 15-Feb-2011 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Keshav Chopra | Director | 15-Feb-2011 | Current |
Financial Performance of Iaso Pharmaceuticals.
Iaso Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 14.5% decrease. The company also saw a substantial fall in profitability, with a 21.02% decrease in profit. The company's net worth Soared by an impressive increase of 11.21%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Iaso Pharmaceuticals?
In 2023, Iaso Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Icch Global Consulting Private LimitedActive 23 years 8 months
Narender Chopra and Keshav Chopra are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Iaso Pharmaceuticals?
Unlock and access historical data on people associated with Iaso Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Iaso Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Iaso Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
